Enzyme replacement therapy for mucopolysaccharidosis VI: long‐term cardiac effects of galsulfase (Naglazyme^®) therapy

This publication has 27 references indexed in Scilit:

• Recommendations for Quantification Methods During the Performance of a Pediatric Echocardiogram: A Report From the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council
  Journal of the American Society of Echocardiography, 2010
• Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long‐term pulmonary function in patients treated with recombinant human N‐acetylgalactosamine 4‐sulfatase
  Journal of Inherited Metabolic Disease, 2010
• The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses
  Cardiology in the Young, 2009
• Mucopolysaccharidosis VI: the Italian experience
  European Journal of Pediatrics, 2009
• Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
  The Journal of Pediatrics, 2006
• Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI
  Clinical Genetics, 2004
• Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
  The Journal of Pediatrics, 2004
• Validity of Echocardiographic Measurement in an Epidemiological Study
  Hypertension, 1999
• Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses
  European Journal of Pediatrics, 1995
• Mitral stenosis in the Maroteaux-Lamy syndrome: a treatable cause of dyspnoea
  1992